 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
First-Line Treatment: Research & News
- Monitoring Board Recommends Stopping Experimental Treatment Regimen in International Study of Patients New to HIV Treatment (May 27, 2008)
From U.S. National Institute of Allergy and Infectious Diseases - Once-a-Month HIV Therapy: Could Nanotechnology Be the Next Treatment Frontier? (April 2008)
A simple explanation of new research on the use of nanotechnology in HIV treatment.
To read PDF, click here
In Project Inform Perspective, from Project Inform - Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
From The Body PRO - Viral Load Between 400 and 20,000 Can Still Maintain Patient Health (September 7, 2004)
Partially suppressive HAART appears to protect against death and illness as well as fully suppressive HAART.
From aidsmap.com - CD4-Guided Pulse Therapy; Induction/Maintenance Therapy: Research From AIDS 2004 (September 2004)
A list of studies examining these two therapy-sparing approaches to HIV treatment.
In TAGline, from Treatment Action Group - Genetics Influence Response to HAART and Incidence of Pancreatitis, Studies Show (August 3, 2004)
From aidsmap.com - French Researchers Question Benefit of Lifelong Antiretroviral Treatment (August 2004)
A small, limited study suggests that after three years of use, HAART may reach the apex of its immunologic benefit.
In TAGline, from Treatment Action Group - Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO - Most Common HAART Regimens Yield Equal Chances of Survival, San Francisco Study Finds (July 12, 2004)
In The XV International AIDS Conference, from The Body PRO - Risk Factors Associated With Delayed Entry to Care (July 12, 2004)
In The XV International AIDS Conference, from The Body PRO - Gender, Youth, Race/Ethnicity, Treatment Interruption Tied to Risk for Virologic Failure (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Clinical Efficacy of Antiretroviral Combination Therapy Based on Protease Inhibitors or Non-Nucleoside Analogue Reverse Transcriptase Inhibitors: Indirect Comparison of Controlled Trials (January 31, 2004)
Three-drug regimens containing a protease inhibitor are found to more effectively suppress HIV than three-drug regimens containing NNRTIs.
In British Medical Journal - Wait Six Months After HIV Treatment Begins to Determine Prognosis, Study Says (August 29, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - No Care Equals Bad Care: A Talk With Sam Bozzette, M.D., Ph.D. (April 2003)
An analysis of what the future holds for patient-centered care.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Key Therapeutic Decisions in Managing HIV Infection (Spring 2003)
An update on when to start, when to switch and when to stop, from STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project - Top Papers of 2002 (January 2003)
Brief summaries of the 12 most important HIV-related publications of last year, compiled by HIV researcher Dr. John G. Bartlett.
In Hopkins HIV Report - What to Start With and What to Include? Should Compounds With Non Cross-Resistance Profiles Be Preferentially Used in Initial or Late Therapy? (November 18, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Antiviral Therapy 2002 (November 17, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Genotyping Less Effective at Predicting Effective Regimens in Children (October 4, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - T-20 May Help Expand Number of Treatable Groups (September 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Identification and Characterization of a Novel Inhibitor of HIV-1 Entry (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Immune Reconstitution and Immunologic Responses to Antiretroviral Therapies: Implications for Therapeutic Strategies (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - A Phase IV Randomized Open-Label Multicenter Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg BID) vs. Saquinavir/Ritonavir (1,000/100 mg BID) in Adult HIV-1 Infection: The Max Cmin 1 Trial (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - HAART and the Management of HIV-1 Infection: Can Short-Term Changes in the Plasma HIV-1 RNA Level Predict Long-Term Response to Therapy? (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Short-Term Immuno-Suppressive Therapy With Prednisolone in HIV-1-Infected Patients Receiving Abacavir With or Without Nevirapine (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Current Controversies in Antiretroviral Therapy and Potential Solutions: Translating Science into Action (July 8, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Optimizing Available Antiretroviral Therapies (February 8, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - The CSF Concentration/IC50 Ratio: A Predictor of CNS Antiretroviral (ARV) Efficacy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Antiretroviral Intensification Accelerates the Decay of the Latent Reservoir of HIV-1 and Decreases but Does Not Eliminate Ongoing Virus Replication (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Low Concentrations of Mycophenolic Acid Augment the Antiretroviral Activity of Abacavir (ABC), Didanosine (ddI), Tenofovir (TFV), and the Combination of ABC and ddI In Vitro (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  |
  |